Consistently, IL-34 downregulation with a specific antisense oligonucleotide reduced activation of ERK1/2 and ELK1, a downstream target of ERK1/2, inhibited CRC cell growth, and enhanced the susceptibility of CRC cells to oxaliplatin-induced death [48]. This evidence concerns the gene MAPK3 and colorectal carcinoma.